Articles From: Epizyme Announces Clinical and Pre-Clinical Data to be Featured in Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting to EPR Properties Announces Pricing of Equity Offering


Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that clinical and pre-clinical data on its first-in-class histone methyltransferase (HMT) inhibitors will be highlighted in oral and poster presentations at the 56 th annual meeting of the American Society of Hematology (ASH), to be held December 6-9 in San Francisco, Calif.
Sign-up for Epizyme Announces Clinical and Pre-Clinical Data to be Featured in Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced, in conjunction with its development partner Eisai, that clinical data from the ongoing Phase 1 study of EPZ-6438 (E7438), an oral, small molecule inhibitor of EZH2, will be featured in a late-breaking oral presentation at the 26 th EORTC-AACR-NCI Symposium on Molecular Targets and Cancer Therapeutics, to be held November 18-21 in Barcelona, Spain.
Sign-up for Epizyme Announces Clinical Data from Phase 1 Trial of EZH2 Inhibitor EPZ-6438 (E7438) to be Presented at EORTC-NCI-AACR Symposium investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that Chief Medical Officer Eric Hedrick, M.D., has resigned from the Company, effective October 31, 2014.
Sign-up for Epizyme Announces Departure of Chief Medical Officer Eric Hedrick, M.D. investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the US Patent and Trademark Office has granted Notices of Allowance for US Patent Applications, Nos.
Sign-up for Epizyme Announces Notices of Allowance for US Patent Applications Covering PRMT5 Inhibitors and Methods of Cancer Treatment with PRMT5 Inhibitors investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced third quarter 2014 operating and financial results and confirmed 2014 guidance.
Sign-up for Epizyme Announces Third Quarter 2014 Financial Results and Provides Corporate Update investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). Epizyme, along with its partner Celgene, is developing EPZ-5676 for the treatment of acute leukemia with alterations in the MLL gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD). The trial found that EPZ-5676 was generally safe and well tolerated across all dose cohorts and showed clinical and biological activity.
Sign-up for Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced that Kenneth Bate, an independent consultant in the biotechnology industry, has been elected to the Company’s board of directors.
Sign-up for Epizyme Elects Kenneth Bate to Board of Directors investment picks
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the results from a preclinical study showing in vitro and in vivo activity of its first-in-class PRMT5 inhibitor EPZ015666 in mantle cell lymphoma (MCL), an aggressive form of non-Hodgkin lymphoma (NHL). PRMT5 is an arginine methyltransferase (RMT), a subset of histone methyltransferases (HMTs), that is overexpressed in multiple human malignancies, including MCL.
Sign-up for Epizyme First-in-Class PRMT5 Inhibitor Demonstrates In Vitro and In Vivo Activity in Models of Mantle Cell Lymphoma investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today presented pre-clinical data on EPZ-6438 (E7438), its oral, small molecule inhibitor of EZH2, in models of synovial sarcoma, a soft tissue sarcoma that typically affects young adults.
Sign-up for Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma investment picks
Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced the publication on the website of the American Society of Hematology (ASH) of an abstract entitled “The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia”. The abstract contains preliminary data from the Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). EPZ-5676 is being developed for the treatment of acute leukemia with alterations in the MLL gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD). The Company plans to present updated data from the trial at the 56 th annual meeting of ASH in San Francisco, Calif.
Sign-up for Epizyme Reports Publication of Preliminary Findings from Phase 1 Study of DOT1L Inhibitor EPZ-5676 in ASH Annual Meeting Abstract investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a conference call and live audio webcast on Thursday, November 6, 2014, at 8:00 a.m. ET to report third quarter 2014 financial results and provide a corporate update.
Sign-up for Epizyme to Report Third Quarter 2014 Financial Results and Provide Corporate Update on November 6, 2014 investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will host a live audio webcast of its discussion of the Company’s clinical programs and pipeline at the ASH annual meeting on Monday, December 8, 2014, at 12:30 p.m. PT (3:30 p.m. ET). The webcast will be available in the Events and Presentations section under the Investor Relations section of the Company's website at www.epizyme.com , and an archived replay of the webcast will be available for 30 days after the presentation.
Sign-up for Epizyme to Webcast Company Presentation at American Society of Hematology (ASH) Annual Meeting on December 8, 2014 investment picks
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in three upcoming events in October: About Epizyme, Inc. Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers.
Sign-up for Epizyme, Inc. to Present at Upcoming Events in October investment picks
2014/10/7
HERNDON, Va., Oct.
Sign-up for ePlus Achieves HP Gold Cloud Builder Specialist Designation investment picks
2014/9/10
HERNDON, Va., Sept.
Sign-up for ePlus Announces Changes to Board of Directors investment picks
2014/10/29
HERNDON, Va., Oct.
Sign-up for ePlus Announces Second Quarter Fiscal Year 2015 Earnings Release Date and Conference Call investment picks
2014/9/23
HERNDON, Va., Sept.
Sign-up for ePlus Becomes an Authorized Surface Reseller in the Microsoft Devices Program investment picks
2014/12/11
HERNDON, Va., Dec.
Sign-up for ePlus Completes Type 2 SSAE 16 Examination for Managed Services Center investment picks
2014/11/5
HERNDON, Va., Nov.
Sign-up for ePlus Enhances Executive Management Team With New EVP of Technology Sales investment picks
2014/12/2
HERNDON, Va., Dec.
Sign-up for ePlus Expands Enhanced Maintenance Support to Include NetApp Technology investment picks
2014/9/25
HERNDON, Va., Sept.
Sign-up for ePlus Expands Managed Services Offering to Support Cisco Meraki Solutions investment picks
2014/12/4
HERNDON, Va., Dec.
Sign-up for ePlus Helps Santa Spread Holiday Cheer to Children in the Hospital this Holiday Season investment picks
2014/11/4
HERNDON, Va., Nov.
Sign-up for ePlus Named NetApp's National FlexPod Partner of the Year investment picks
2014/11/13
HERNDON, Va., Nov.
Sign-up for ePlus Offers Enhanced FlexPod Managed Services to Facilitate Cloud Management investment picks
2014/11/3
HERNDON, Va., Nov.
Sign-up for ePlus Receives Cisco's 2014 Advanced Collaboration Partner of the Year Contact Center Express Award investment picks
2014/9/18
HERNDON, Va., Sept.
Sign-up for ePlus Recognized by Cisco for Excellence in Customer Satisfaction in the United States investment picks
2014/11/5
Quarterly Highlights: Revenue increased 9.7% Gross margin on products and services expanded to 19.5% from 17.8%; consolidated gross margin was 21.5% Operating income increased 38.3% Earnings per diluted share reached $1.63, up 53.8% HERNDON, Va., Nov.
Sign-up for ePlus Reports Second Quarter and First Half Financial Results investment picks
2014/10/2
HERNDON, Va., Oct.
Sign-up for ePlus Technology Achieves Five Cisco Recertifications investment picks
EPR Properties (NYSE:EPR) announced today that it has commenced an underwritten public offering of 3,200,000 of its common shares of beneficial interest.
Sign-up for EPR Properties Announces Equity Offering investment picks
EPR Properties (NYSE:EPR) announced today the pricing of its underwritten public offering of 3,200,000 of its common shares of beneficial interest at a price of $52.25 per share.
Sign-up for EPR Properties Announces Pricing of Equity Offering investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Epizyme Announces Clinical and Pre-Clinical Data to be Featured in Oral and Poster Presentations at American Society of Hematology (ASH) Annual Meeting to EPR Properties Announces Pricing of Equity Offering
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent